Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of Locally Produced 18F-FDG for PET/CT Scans
NCT04615156Phase 3Not yet recruiting
- Sponsor
- Eastern Health
- Start
- Nov 2020
- Primary completion
- Nov 2027
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of fludeoxyglucose f 18, sponsored by Eastern Health. Primary endpoint: Incidence of Adverse Events at 4 hours. Planned start Nov 2020; status: not yet recruiting.
02
Drugs
fludeoxyglucose f 18
Beyond the preview
Go deeper on NCT04615156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615156.